Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response

다국어 초록 (Multilingual Abstract)

Objective-S100B is a neurotrophic factor that is involved in neuroplasticity. Neuroplasticity is disrupted in depression; however, treatment with antidepressants can restore neuroplasticity. S100B has previously been used as a biological marker for neuropathology and neuroplasticity; therefore, in this study, we compared serum S100B levels in depressive
patients to those of normal controls. In addition, we compared the serum S100B levels of antidepressant responders to those of nonresponders.

Methods-Thirty five normal controls and 59 depressive patients were enrolled in this study. Depressive patients entered a 6 week clinical trial that included treatment with antidepressants. The serum S100B levels and clinical assessments, which included Hamilton depression rating scores, were measured at baseline and after 6 weeks of treatment with antidepressants. The difference in the serum S100B levels between depressive patients and normal controls and between antidepressant responders and nonresponders was then compared.

Results-There were no significant differences in the serum S100B levels of normal controls and depressive patients. In addition, 30 of the depressive patients responded to antidepressant treatment while 29 did not. Finally, the responders had significantly higher baseline serum S100B levels than the nonresponders.

Conclusion-The results of this study suggest that the baseline serum S100B level is associated with the subsequent response to antidepressants. In addition, the high baseline serum S100B level that was observed in depressive patients may enhance neuroplasticity, which results in a favorable therapeutic response to antidepressants.

목차 (Table of Contents)

• INTRODUCTION
• METHODS
• RESULTS
• DISCUSSION
• ACKNOWLEDGEMENTS
• REFERENCES

참고문헌 (Reference)

1 구형모, "학술 일상활동평가-기초의 신뢰도 및 타당도 연구" 대한노인병학회 8 (8): 206-214, 2004

2 Ijuin M, "Validation of the 7-Minute Screen for the detection of early-stage Alzheimer’s disease" 25 : 248-255, 2008

3 Hetzel G, "The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment" 178 : 161-166, 2005

4 Maya Vetencourt JF, "The antidepressant fluoxetine restores plasticity in the adult visual cortex" 320 : 385-388, 2008

5 Lingjaerde O, "The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptictreated patients" 334 : 1-100, 1987

6 Zimmer DB, "The S100 protein family: history, function, and expression" 37 : 417-429, 1995

7 Schäfer BW, "The S100 family of EF-hand calciumbinding proteins: functions and pathology" 21 : 134-140, 1996

8 Carson MJ, "The 5HT5A serotonin receptor is expressed predominantly by astrocytes in which it inhibits cAMP accumulation: a mechanism for neuronal suppression of reactive astrocytes" 17 : 317-326, 1996

9 Duman RS, "Synaptic plasticity and mood disorders" 7 (7): S29-S34, 2002

10 Pittenger C, "Stress, depression, and neuroplasticity: a convergence of mechanisms" 33 : 88-109, 2008

11 Whitaker-Azmitia PM, "Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology" 528 : 155-158, 1990

12 Tardito D, "Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanism in the action of antidepressants: a critical overview" 58 : 115-134, 2006

13 Schroeter ML, "Serum markers support disease-specific glial pathology in major depression" 2008

14 Kim DK, "Serotonin transporter gene polymorphism and antidepressant response" 11 : 215-219, 2000

15 Kogel D, "S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: Clinical implications for the role of S100B in excitotoxic brain injury" 127 : 913-920, 2004

16 Schmitt KR, "S100B modulates IL-6 release and cytotoxicity from hypothermic brain cells and inhibits hypothermia-induced axonal outgrowth" 59 : 68-73, 2007

17 Schroeter ML, "S100B is increased in mood disorders and may be reduced by antidepressive treatment" 13 : 1675-1678, 2002

18 Rothermundt M, "S100B is increased in melancholic but not in non-melancholic major depression" 66 : 89-93, 2001

19 Rothermundt M, "S100B in brain damage and neurodegeneration" 60 : 614-632, 2003

20 Arolt V, "S100B and response to treatment in major depression: a pilot study" 13 : 235-239, 2003

21 Donato R, "S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles" 33 : 637-668, 2001

22 Santarelli L, "Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants" 301 : 805-809, 2003

23 Abdul-Khaliq H, "Protein S-100beta in brain and serum after deep hypothermic circulatory arrest in rabbits: relationship to perivascular astrocytic swelling" 38 : 1169-1172, 2000

24 Lee HY, "Plasma Brain-Derived Neurotrophic Factor as a Peripheral Marker for the Action Mechanism of Antidepressants" 57 : 194-199, 2008

25 Marchi N, "Peripheral markers of blood-brain barrier damage" 342 : 1-12, 2004

26 Manji HK, "Neuroplasticity and cellular resilience in mood disorders" 5 : 578-593, 2000

27 Pinto SS, "Immunocontent and secretion of S100B in astrocyte cultures from different brain regions in relation to morphology" 486 : 203-207, 2000

28 Paizanis E, "Hippocampal neurogenesis, depressive disorders, and antidepressant therapy" 73754-, 2007

29 Steiner J, "Evidence for a wide extra-astrocytic distribution of S100B in human brain" 8 : 2-, 2007

30 Kleindienst A, "Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury" 22 : 645-655, 2005

31 American Psychiatric Association, "Diagnostic and statistical manual of mental disorders (4th ed.)" American Psychiatric Association 1994

32 Arantes-Goncalves F, "Depression and treatment. Apoptosis, neuroplasticity and antidepressants" 19 : 9-20, 2006

33 Daszuta A, "Depression and neuroplasticity: implication of serotoninergic systems" 60 : 461-468, 2005

34 Karege F, "Decreased serum brain-derived neurotrophic factor levels in major depressed patients" 109 : 143-148, 2002

35 Santamaria-Kisiel L, "Calcium-dependent and -independent interactions of the S100 protein family" 396 : 201-214, 2006

36 Ponath G, "Autocrine S100B effects on astrocytes are mediated via RAGE" 184 : 214-222, 2007

37 Porter JT, "Astrocytic neurotransmitter receptors in situ and in vivo" 51 : 439-455, 1997

38 Henkel AW, "Antidepressant drugs modulate growth factors in cultured cells" 8 : 6-, 2008

39 D’Sa C, "Antidepressant and neuroplasticity" 4 : 183-194, 2002

40 Beck AT, "An inventory for measuring depression" 4 : 561-571, 1961

41 Kang Y, "A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients" 15 : 300-308, 1997

42 Christensen KJ, "A cognitive battery for dementia: development and measurement characteristics" 3 : 168-174, 1991